
Kestra Medical (KMTS) announced publication of primary results from the ASSURE WCD Clinical Evaluation Post-Approval Study, or ACE-PAS, in the Journal of Cardiovascular Electrophysiology. The largest prospective real-world study of
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| KMTS | Kestra Medical Technologies Ltd. | 26.78 | 1.65 | 6.56% |
| Name | Price | % Change | |
|---|---|---|---|
| $26.78 | +6.56% |

Kestra Medical (KMTS) announced publication of primary results from the ASSURE WCD Clinical Evaluation Post-Approval Study, or ACE-PAS, in the Journal of Cardiovascular Electrophysiology. The largest prospective real-world study of

BofA raised the firm’s price target on Kestra Medical (KMTS) to $33 from $30 and keeps a Buy rating on the shares. Medical technology investor sentiment is “slightly less negative”

Evercore ISI analyst Vijay Kumar initiated coverage of Kestra Medical (KMTS) with an Outperform rating and $34 price target Kestra makes the ASSURE wearable defibrillator and competes with ZOLL Medical’s

Kestra Medical Technologies Ltd. (($KMTS)) has held its Q1 earnings call. Read on for the main highlights of the call. Kestra Medical Technologies’ latest earnings call struck a distinctly upbeat

Stock futures are pointing to another lower open as investors brace for the Federal Reserve to begin its two-day policy meeting, with the central bank widely expected to raise interest

In a report released yesterday, Marie Thibault from BTIG reiterated a Buy rating on Kestra Medical Technologies Ltd., with a price target of $32.00. Marie Thibault has given his Buy

Travis Steed, an analyst from Bank of America Securities, reiterated the Buy rating on Kestra Medical Technologies Ltd.. The associated price target remains the same with $30.00. Travis Steed has

“Pacing the frontier” of AI development, expressed by the CEO of Anthropic in a high-profile blog post this weekend ,was added to the wall of worry for investors, sending the

16:35 EDT Kestra Medical (KMTS) down 7% at $22.32 after Q1 earnings miss Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See

Reports Q1 revenue $30.97M, consensus $29.01M. “Kestra delivered another strong quarter of financial performance, generating revenue growth of 60% while expanding gross margin to over 56%,” said Brian Webster, president
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Dec 10, 2026TBA | $1.59B | $-0.61 | $32.09M | 0.16 | -9.97 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.